{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:46:04Z","timestamp":1787697964676,"version":"build-2784847793"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018231","name":"Aligning Science Across Parkinson's","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jbc.2025.110376","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:58:28Z","timestamp":1749898708000},"page":"110376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Structural biology of Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 (LRRK2)"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-7023","authenticated-orcid":false,"given":"Andres E.","family":"Leschziner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110376_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-030122-051144","article-title":"Leucine-rich repeat kinases","volume":"93","author":"Alessi","year":"2024","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jbc.2025.110376_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson\u2019s disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbc.2025.110376_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.10113","article-title":"A new locus for Parkinson\u2019s disease (PARK8) maps to chromosome 12p11.2-q13.1","volume":"51","author":"Funayama","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jbc.2025.110376_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jbc.2025.110376_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jbc.2025.110376_bib6","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110376_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddi439","article-title":"The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity","volume":"15","author":"Gloeckner","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2025.110376_bib8","doi-asserted-by":"crossref","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson\u2019s disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2025.110376_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.jbc.2025.110376_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1091\/mbc.e16-10-0737","article-title":"Rab GTPases: master regulators that establish the secretory and endocytic pathways","volume":"28","author":"Pfeffer","year":"2017","journal-title":"Mol. Biol. Cell."},{"key":"10.1016\/j.jbc.2025.110376_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/febs.15453","article-title":"Rab family of small GTPases: an updated view on their regulation and functions","volume":"288","author":"Homma","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.jbc.2025.110376_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/21541248.2017.1336191","article-title":"Rab GTPases and their interacting protein partners: structural insights into Rab functional diversity","volume":"9","author":"Pylypenko","year":"2018","journal-title":"Small. GTPases."},{"key":"10.1016\/j.jbc.2025.110376_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31012","article-title":"Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis","volume":"6","author":"Steger","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.jbc.2025.110376_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.538","article-title":"Characterization of a selective inhibitor of the Parkinson\u2019s disease kinase LRRK2","volume":"7","author":"Deng","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2025.110376_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbc.2025.110376_bib16","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","article-title":"Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"55","author":"Estrada","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110376_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.jbc.2025.110376_bib18","article-title":"Type-II kinase inhibitors that target Parkinson\u2019s Disease-associated LRRK2","author":"Raig","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2025.110376_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk6191","article-title":"Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Sanz Murillo","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2025.110376_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-023-00639-8","article-title":"Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell. Discov."},{"key":"10.1016\/j.jbc.2025.110376_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/ijms20010147","article-title":"Roco proteins: GTPases with a baroque structure and mechanism","volume":"20","author":"Wauters","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2025.110376_bib22","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.3390\/ijms19124074","article-title":"Roco proteins and the Parkinson\u2019s disease-associated LRRK2","volume":"19","author":"Liao","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2025.110376_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110376_bib24","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","article-title":"Structural analysis of the full-length human LRRK2","volume":"184","author":"Myasnikov","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110376_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson\u2019s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity","volume":"16","author":"West","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2025.110376_bib26","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.yexcr.2007.07.007","article-title":"The Parkinson\u2019s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity","volume":"313","author":"Guo","year":"2007","journal-title":"Exp. Cel. Res."},{"key":"10.1016\/j.jbc.2025.110376_bib27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/bi061960m","article-title":"GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson\u2019s disease","volume":"46","author":"Ito","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2025.110376_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbrc.2009.08.163","article-title":"The Parkinson\u2019s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites","volume":"389","author":"Greggio","year":"2009","journal-title":"Biochem. Biophysical. Res. Commun."},{"key":"10.1016\/j.jbc.2025.110376_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023207","article-title":"LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding","volume":"6","author":"Taymans","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2025.110376_bib30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmb.2011.07.033","article-title":"Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities","volume":"412","author":"Webber","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jbc.2025.110376_bib31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/hmg\/dds522","article-title":"GTPase activity regulates kinase activity and cellular phenotypes of Parkinson\u2019s disease-associated LRRK2","volume":"22","author":"Biosa","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2025.110376_bib32","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/hmg\/ddx161","article-title":"GTP binding regulates cellular localization of Parkinson\u2019s disease-associated LRRK2","volume":"26","author":"Blanca Ram\u00edrez","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2025.110376_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1042\/BCJ20220161","article-title":"Impact of 100 LRRK2 variants linked to Parkinson\u2019s disease on kinase activity and microtubule binding","volume":"479","author":"Kalogeropulou","year":"2022","journal-title":"Biochem J"},{"issue":"Suppl 3","key":"10.1016\/j.jbc.2025.110376_bib34","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S1353-8020(09)70815-6","article-title":"Clinical features of LRRK2 parkinsonism","volume":"15","author":"Haugarvoll","year":"2009","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.jbc.2025.110376_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson\u2019s disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbc.2025.110376_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbc.2025.110376_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mds.26892","article-title":"LRRK2 levels and phosphorylation in Parkinson\u2019s disease brain and cases with restricted Lewy bodies","volume":"32","author":"Dzamko","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jbc.2025.110376_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-49969-7_6","article-title":"Molecular insights and functional implication of LRRK2 dimerization","volume":"14","author":"Civiero","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.jbc.2025.110376_bib39","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.1817889116","article-title":"Crystal structure of the WD40 domain dimer of LRRK2","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110376_bib40","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.0709098105","article-title":"Structure of the ROC domain from the Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase","volume":"105","author":"Deng","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110376_bib41","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1021\/bi100157u","article-title":"Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation","volume":"49","author":"Berger","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2025.110376_bib42","article-title":"14-3-3 binding maintains the Parkinson\u2019s associated kinase LRRK2 in an inactive state","author":"Martinez Fiesco","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2025.110376_bib43","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/hmg\/ddr526","article-title":"LRRK2 Parkinson disease mutations enhance its microtubule association","volume":"21","author":"Kett","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2025.110376_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79771","article-title":"A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation","volume":"11","author":"Vides","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jbc.2025.110376_bib45","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87098","article-title":"Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson\u2019s disease-linked LRRK2 kinase","volume":"12","author":"Dhekne","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.jbc.2025.110376_bib46","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ structure of Parkinson\u2019s disease-linked LRRK2","volume":"182","author":"Watanabe","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110376_bib47","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.adi9926","article-title":"Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2","volume":"382","author":"Zhu","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.110376_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41594-022-00863-y","article-title":"Structural basis for Parkinson\u2019s disease-linked LRRK2\u2019s binding to microtubules","volume":"29","author":"Snead","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbc.2025.110376_bib49","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41594-023-01109-1","article-title":"Structure of LRRK1 and mechanisms of autoinhibition and activation","volume":"30","author":"Reimer","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbc.2025.110376_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk6191","article-title":"Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Sanz Murillo","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2025.110376_bib51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-biochem-052410-090317","article-title":"The structural basis for control of eukaryotic protein kinases","volume":"81","author":"Endicott","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jbc.2025.110376_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-397918-6.00002-1","article-title":"A structural atlas of kinases inhibited by clinically approved drugs","volume":"548","author":"Wang","year":"2014","journal-title":"Methods. Enzymol."},{"key":"10.1016\/j.jbc.2025.110376_bib53","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"8","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110376_bib54","article-title":"Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2","author":"Chen","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2025.110376_bib55","article-title":"Role and mechanism of action of leucine-rich repeat kinase 1 in bone","volume":"5","author":"Xing","year":"2017","journal-title":"Bone. Res."},{"key":"10.1016\/j.jbc.2025.110376_bib56","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1038\/s41467-023-40532-2","article-title":"Structure and regulation of full-length human leucine-rich repeat kinase 1","volume":"14","author":"Metcalfe","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2025.110376_bib57","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1042\/BCJ20220308","article-title":"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain","volume":"479","author":"Malik","year":"2022","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbc.2025.110376_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","article-title":"RAB32 Ser71Arg in autosomal dominant Parkinson\u2019s disease: linkage, association, and functional analyses","volume":"23","author":"Gustavsson","year":"2024","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.jbc.2025.110376_bib59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41588-024-01787-7","article-title":"Systematic rare variant analyses identify RAB32 as a susceptibility gene for familial Parkinson\u2019s disease","volume":"56","author":"Hop","year":"2024","journal-title":"Nat. Genet."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:32:53Z","timestamp":1756423973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825022264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0021925825022264"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110376","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural biology of Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 (LRRK2)","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110376"}}